US 12,226,399 B2
Oral aqueous suspension formulation comprising carbamate compound
Pravada Pendse, Lake Hopatcong, NJ (US); Murali M Bommana, Monroe Township, NJ (US); Regina H. Noh, Hackensack, NJ (US); Augustin Pegan, Riverdale, NJ (US); Travis John Webb, St. Petersburg, FL (US); and Jejuan Maxwell, Clearwater, FL (US)
Assigned to SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Filed by SK BIOPHARMACEUTICALS CO., LTD., Gyeonggi-do (KR)
Filed on May 27, 2022, as Appl. No. 17/826,289.
Claims priority of provisional application 63/194,276, filed on May 28, 2021.
Prior Publication US 2023/0013175 A1, Jan. 19, 2023
Int. Cl. A61K 31/41 (2006.01); A61K 9/10 (2006.01); A61K 47/02 (2006.01); A61K 47/10 (2017.01); A61K 47/32 (2006.01); A61K 47/34 (2017.01); A61K 47/36 (2006.01); A61K 47/38 (2006.01); A61P 25/00 (2006.01)
CPC A61K 31/41 (2013.01) [A61K 9/10 (2013.01); A61K 47/02 (2013.01); A61K 47/10 (2013.01); A61K 47/32 (2013.01); A61K 47/38 (2013.01)] 30 Claims
 
1. An aqueous formulation comprising a carbamate compound of Formula 1, or a pharmaceutically acceptable salt, solvate or hydrate thereof, poloxamer, and an aqueous carrier:

OG Complex Work Unit Chemistry
wherein,
R1 and R2 are each independently selected from the group consisting of —H, halo, C1-C8 alkyl, halo-C1-C8 alkyl, C1-C8 thioalkoxy, and C1-C8 alkoxy; and
one of A1 and A2 is CH, and the other is N,
wherein the aqueous formulation is in the form of a suspension formulation.